Zeng, Rebecca
Vingopoulos, Filippos
Wang, Mengyu
Bannerman, Augustine
Wescott, Hannah E.
Baldwin, Grace
Katz, Raviv
Koch, Thomas
Elze, Tobias
Kim, Leo A.
Vavvas, Demetrios G.
Husain, Deeba
Miller, John B. http://orcid.org/0000-0003-0109-9738
Funding for this research was provided by:
National Eye Institute (NIH P30 EY003790, NIH R00 EY028631)
Alcon Research Institute (Young Investigator Award)
Article History
Received: 27 April 2022
Revised: 28 July 2022
Accepted: 23 August 2022
First Online: 23 September 2022
Declarations
:
: This study involves human participants and was approved by the institutional review board at Massachusetts Eye and Ear.
: Consent was waived due to the retrospective nature of the study.
: LAK has received research support from the National Eye Institute (R01EY027739) and CureVac AG and has a financial arrangement with Pykus Therapeutics. DH is a consultant for Allergan, Genentech, Omeicos Therapeutics and has received financial support from the National Eye Institute, Lions VisionGift, Commonwealth Grant, Lions International, Syneos LLC, and the Macular Society. DGV is a consultant for Valitor and OliX Pharmaceuticals and has received financial support from the National Eye Institute and by grants from the National Institute of Health (R01EY025362 and R21EY0203079), Research to Prevent Blindness, Loeffler’s Family Foundation, Yeatts Family Foundation, and Alcon Research Institute. JBM is a consultant for Alcon, Allergan, Carl Zeiss, Sunovion, and Genentech.